• Blood loss and immune reaction are closely related to morbidity and recovery after surgery.
Essentials
• Blood loss and immune reaction are closely related to morbidity and recovery after surgery.
• We studied the effect of epinephrine plus tranexamic acid on blood loss and immune reaction.
• Epinephrine plus tranexamic acid reduced postoperative total blood loss and immune reaction.
• Epinephrine plus tranexamic acid did not increase the incidence of complications.
Summary. Background: Hemostasis, thrombosis and surgical stress-induced immune reactions are important for perioperative morbidity and recovery after major surgical operations. Objectives: To evaluate the effects of combined administration of low-dose epinephrine (LDEPI) and tranexamic acid (TXA) on perioperative blood loss, thromboembolic complications and inflammatory responses in patients undergoing total hip arthroplasty (THA). Patients/Methods: Patients scheduled for THA (n = 195) were randomized into three interventions: intravenous LDEPI plus TXA (group IV); topical diluted epinephrine plus TXA (group TP); and TXA alone as control (group CT). The primary outcome was perioperative blood loss on postoperative day (POD) 1. Secondary outcomes included perioperative blood loss on POD 3, intraoperative blood loss, volume of drainage, transfusion values, coagulation and fibrinolysis parameters, inflammatory cytokine levels, cases of thrombosis, intravenous fluid on the operation day, and length of hospital stay. Results: The mean calculated amounts of total blood loss in groups IV, TP and CT were 631.2 mL, 760.5 mL, and 825.6 mL, respectively, on POD 1; treatment effects (differences) were 194.4 mL (95% confidence interval [CI] 146.7-242.0) and 65.0 mL (95% CI 17.4-112.7). Groups IV and TP had lower levels of proinflammatory cytokines (tumor necrosis factor-a and interleukin [IL]-1b) and higher levels of the anti-inflammatory cytokine IL-10, and showed faster development of coagulation and fibrinolysis (without change in peak levels), than group CT early postoperation. No differences were observed in transfusion, thromboembolic and other outcomes among the groups. Conclusion: The combined administration of LDEPI and TXA was more effective in reducing perioperative blood loss and alleviating the inflammatory response than TXA alone, without
Introduction
In recent years, surgical techniques and enhanced recovery after surgery (ERAS) guidelines have made great strides in many surgical settings. However, major surgery remains associated with great perioperative blood loss, thromboembolic complications, and excessive surgical stress-induced immune reactions, which are closely related to postoperative morbidity and ERAS [1, 2] , especially in major orthopedic surgical operations [3] . Therefore, enhancing hemostasis while simultaneously reducing the risk of thrombosis and inflammatory reactions postoperatively is important in many surgical settings.
Tranexamic acid (TXA), a synthetic antifibrinolytic agent, is routinely used in joint replacement. TXA was used to reduce perioperative blood loss in various surgical settings, and was found to have anti-inflammatory effects [4] . Epinephrine (EPI) is another hemostatic agent that has been used to reduce perioperative blood loss in various surgical operations [5] [6] [7] . Low-dose EPI (LDEPI) infusion promoted platelet aggregation and spleen contraction and enhanced thrombocytopoiesis by activating a-adrenoreceptors, resulting in an instant 20-30% increase in the peripheral count of platelets, especially that of larger platelets [8] [9] [10] . Activating b-adrenoreceptors could also stimulate the activity or release of several coagulation and fibrinolysis molecules, such as factor VIII, von Willebrand factor antigen, and tissue-type plasminogen activator, into the circulation [9] . In addition, EPI may have a net anti-inflammatory effect [11] . Lower serum levels of tumor necrosis factor (TNF)-a and interleukin (IL)-1b, and higher serum levels of the antiinflammatory cytokine IL-10, were observed after the administration of EPI in vivo [11, 12] . However, owing to its systematic effects, EPI has more frequently been administered as local injections than as systemic infusions. The combined administration of EPI and TXA has been reported in a few studies; however, the effects of this combined administration are not completely known.
The aim of this randomized placebo-controlled trial was to assess the additional effects of the combined administration of LDEPI and TXA on hemostasis, thrombosis and anti-inflammation in patients undergoing total hip arthroplasty (THA), such as blood loss and the rate of blood transfusion, the occurrence of thromboembolic complications, and serum inflammatory factor levels.
Materials and methods

Trial oversight
This randomized placebo-controlled trial was registered on www.ClinicalTrials.gov (NCT02864095), and approved by the Ethical Committee of our institute. All methods involving human participants were conducted in accordance with the ethical standards outlined in the Declaration of Helsinki. Informed consent was obtained from each patient. All authors had access to the primary clinical trial data.
Participants
From June 2016 to April 2017, patients aged 20-65 years who were diagnosed with osteonecrosis of the femoral head or hip osteoarthritis and scheduled for a unilateral primary THA were eligible for this trial. The exclusion criteria were: allergy to TXA; a hemoglobin (Hb) level of < 10 g dL
À1
; a serum potassium level of < 3.0 mmol L À1 ; 
Grouping and trial intervention
Patients were randomized into the following three groups by use of a computer-generated randomization 
Perioperative management strategies
Blood transfusion was applied when the Hb level was < 70 g L À1 or 70-100 g L À1 with any anemia-related organ dysfunction, such as an alteration in mental status or tachycardia. Comprehensive venous thromboembolism prevention strategies were adopted. Lower-extremity strength exercises, such as quadriceps strength exercise, ankle flexion and extension exercise, active and passive range of motion exercise, and walking exercise, were conducted. Intermittent pneumatic compression of the calf was performed until the patient could ambulate using a cane walker or crutch. Furthermore, LMWH (0.2 mL, 2000 IU; Clexane; Sanofi-Aventis, Paris, France) was first injected 6 h after surgery and then every 24 h (0.4 mL, 4000 IU) until hospital discharge. After discharge, 10 mg of rivaroxaban (Xarelto; Bayer, Leverkusen, Germany) was administered orally for 15 days. Diagnostic Doppler ultrasound examination was routinely performed on postoperative day (POD) 3 and during a 1-month follow-up to detect deep vein thrombosis. If this resulted in a clinical suspicion of pulmonary embolism or deep vein thrombosis, enhanced computed tomography pulmonary arteriography and ultrasound examination were conducted immediately.
Outcome measures
The primary outcome measures were perioperative blood loss on POD 1 calculated with the Gross formula [13] , with total blood volume being estimated with Nadler's equation [14] . The secondary outcome measures were intraoperative blood loss, volume of drainage, perioperative blood loss on POD 3, transfusion values, coagulation and fibrinolysis parameters, inflammatory cytokine levels, number of cases of deep vein thrombosis or pulmonary embolism, intravenous fluid on the operation day, and length of postoperative hospital stay. Other complications, such as infections, were also recorded. Intraoperative blood loss was calculated by measuring suction drain contents and weighing gauzes at the end of surgery. Hb level, hematocrit (Hct) and platelet count were determined preoperatively and on PODs 1, 3, and 7. Coagulation and fibrinolysis parameters were determined preoperatively, intraoperatively, and at 1 h, 3 h, 6 h, 12 h and 24 h postoperatively by thromboelastographic (TEG) (TEG5000; Haemoscope, Niles, IL, USA) analyses. Blood samples for TEG analyses were activated with kaolin and placed in a heparinase cup. TEG variables included reaction time, rate of thrombus formation, maximum amplitude, a-angle (rate of thrombus formation), the lysis rate at 30 min, and coagulation index (overall coagulation status). Selected parameters of proinflammation and anti-inflammation, such as the proinflammatory cytokines IL-1b, IL-6, TNF-a, and the anti-inflammatory cytokine IL-10, were measured by ELISA.
Statistical analysis
The trial was performed as a superiority trial. The required sample size was estimated on the basis of on previous data from our institute, which demonstrated a total blood loss of 642 mL (standard deviation [SD] 141 mL) on POD 1. Fifty-nine patients were required for each group, with an a (significance level) of 0.05 (both sides) and a power of 90%, on the assumption that intravenous or topical EPI would reduce total blood loss by at least 15% (96 mL) on POD 1. Therefore, we included 65 subjects for each group in the trial, assuming 10% loss to follow-up. Before data analyses, demographics and outcomes were evaluated for a normal distribution by the use of histograms and quantile-quantile plots. Normally distributed continuous data were presented as the mean (SD), frequencies and percentages for binomial data. Continuous data were compared among groups by the use of one-way ANOVA with Fisher's least significant difference post hoc testing; categorical data were compared by use of the v 2 test. For all outcome measures, a P-value of < 0.05 (twosided) was considered to be statistically significant. Data analyses were performed with SPSS, Version 13.0 (SPSS, Chicago, IL, USA). All statistical analyses were performed in a blinded manner.
Results
Subjects
From June 2016 to April 2017, 262 consecutive patients were screened for eligibility. The duration of follow-up was 1 month. Thirty-six patients were excluded according to the exclusion criteria, 26 patients refused to participate, and five patients dropped out of the study for other reasons. Therefore, 65 patients were randomized into each group (groups IV, TP, and CT; Fig. 1 ). All 195 patients completed the entire follow-up regarding the primary and secondary outcomes. Baseline characteristics were comparable among the allocation groups (Table 1) .
Study outcomes
The overall mean duration of surgery was 50.8 min (SD 9.5 min). Outcomes regarding blood loss and transfusion are shown in Table 2 and Fig. 2 . Intraoperative blood loss, which was evaluated by measuring suction drain content and weighing gauzes at the end of surgery, was similar between groups. The mean calculated amounts of total blood loss in groups IV, TP and CT were 631.2 mL (SD 117.9 mL), 760.5 mL (SD 137.9 mL), and 825.6 mL (SD 154.7 mL), respectively, on POD 1 (primary outcome). Groups IV and TP had mean reductions of 194. ASA, American Society of Anesthesiologists; SD, standard deviation. Group IV: received intravenous low-dose epinephrine (LDEPI) (1 mg of epinephrine [EPI] mixed with 100 mL of normal saline plus topical placebo of 0.25 mL of normal saline) at a pump speed of 0.05 lg kgÀ1 minÀ1 from the initiation of anesthesia to the end of surgery. Group TP: received intravenous placebo (normal saline, at a pump speed of 0.005 mL kgÀ1 minÀ1) plus topical LDEPI (0.25 mg of diluted EPI [1 : 200 000]). Group CT: received intravenous placebo (normal saline) plus topical placebo (normal saline).
Fig. 2. Group IV had significantly smaller decreases in
Hb level, Hct level and platelet count than the other groups on PODs 1 and 3. The amounts of drainage blood loss were 109.7 mL (SD 29.2 mL), 118.1 mL (SD 47.7 mL) and 140.8 mL (SD 56.1 mL) in groups IV, TP, and CT, respectively, with significant intergroup differences (except for groups IV and CT; P = 0.301). Group IV had a smaller transfusion rate and transfusion volume than the other two groups, however, no significant differences were found among the three groups (Table 2) . Therefore, both intravenous and topical administration of LDEPI significantly decreased the total blood loss as compared with the control group.
According to the TEG analysis, enhanced coagulation and fibrinolysis functions were observed in all three groups postoperatively, with increasing coagulation index (Fig. 3) . This result indicated that coagulation and fibrinolysis increased from the intraoperative period and peaked at 6 h postoperatively. Intravenous LDEPI increases the speed of coagulation and fibrinolysis, without increasing the peak values.
Inflammatory cytokine analysis results are shown in Fig. 4 . Proinflammatory and anti-inflammatory cytokine levels increased from the intraoperative period, peaked early in the postoperative period, and then declined. Furthermore, group IV had significantly smaller increases in the levels of proinflammatory cytokines (i.e. TNF-a and IL-1b) than the other two groups within the 6-h postoperative period. On the basis of the anti-inflammatory cytokine analysis, group IV had higher serum IL-10 levels within the 6-h postoperative period than groups TP and CT. Therefore, intravenous administration of LDEPI had a net anti-inflammatory effect. There were no significant differences in the duration of the postoperative hospital stay, deep vein thrombosis and plexus venous leg muscle thrombosis among the three groups. No pulmonary embolism or other complications, such as infection, wound complications, adverse events, and drug reactions, related to EPI administration were observed in any of the patients (Table 2) .
Discussion
Reducing perioperative blood loss, thromboembolic complications and excessive surgical stress-induced immune reactions is critical for reducing perioperative morbidity after major surgical operations [15, 16] . THA is a representative major surgical operation in orthopedics, and is widely used for treating end-stage osteonecrosis of the femoral head and osteoarthritis [17] . This randomized placebo-controlled trial was designed to verify that LDEPI could decrease perioperative blood loss and alleviate inflammatory reactions without increasing the incidence of thromboembolic complications in patients undergoing THA.
The efficacy of TXA in reducing blood loss and transfusion in THA patients has been reported in several studies [2, 18] . However, intravenous administration of EPI in joint replacement patients is a matter of debate, owing to the risk of thrombosis [19, 20] . It was reported that LDEPI infusion plus TXA could significantly reduce perioperative blood loss without increasing the risk of adverse events [7] . However, the coagulation and fibrinolysis changes after administration of LDEPI plus TXA were unclear, because of a lack of concomitant coagulation monitoring. Therefore, TEG analysis was used to monitor the dynamic changes in coagulation and fibrinolysis in this trial. To the best of our knowledge, this is the first study in which the perioperative effects of administering LDEPI plus TXA in THA patients have been closely examined. In the present study, no intergroup differences in intraoperative blood loss were observed. However, postoperative total blood loss was significantly reduced in groups IV and TP. Although a lower TXA dose was used in this study than in a previous study (10 mg/kg intravenously + 3 g by intra-articular injection versus 15 mg kg À1 intravenously + 3 g by intra-articular injection, respectively), we observed a lower total blood loss [21] . We observed mean total blood losses of 631.2 mL (SD 117.9 mL) and 769.4 mL (SD 146.5 mL) on PODs 1 and 3, respectively, in group IV, whereas a total blood loss of 835.49 mL (SD 343.50 mL) on POD 3 was reported in the previous study [21] . The mean total blood loss in group IV was 23.5% and 18.6% lower than those in group CT on POD 1 (a difference of 194.4 mL) and POD 3 (a difference of 175.3 mL), respectively. Furthermore, the mean total blood loss in group TP was 7.9% and 9.8% lower than that in group CT on PODs 1 and 3, respectively. Therefore, intravenous and topical administration of LDEPI plus TXA could effectively reduce blood loss by approximately 20% and 10%, respectively, as compared with TXA alone. Furthermore, group IV was observed to have a lower transfusion rate and lower transfusion volume than groups TP and CT. The transfusion rate in group CT was approximately 10.8%, as compared with 1.5% and 3.1% in groups IV and TP, respectively. However, these differences were not statistically significant. It has been strongly suggested that EPI administration could be beneficial for reducing blood loss, especially if it is given intravenously. Topical administration of EPI decreases blood loss; however, it does not affect systematic coagulation and fibrinolysis. We believe that the reduction in blood loss is influenced by the contraction of peripheral vessels and the extension of the effective duration of topical administration of TXA, because the antifibrinolytic effect of TXA is synergistic with the vasoconstrictive effect of EPI [5, 22] . The incidence of early postoperative thromboembolic complications was not increased by the administration of LDEPI. On the basis of TEG analysis, intravenous LDEPI increased the speed of enhancement of postoperative coagulation and fibrinolysis functions. However, this effect mainly occurs within 3 h postoperatively, which is the major bleeding period. Furthermore, intravenous LDEPI did not increase the peak coagulation and fibrinolysis parameters as compared with groups TP and CT. No intergroup differences in the number of patients with a hypercoagulable status were observed among groups according to the coagulation index. Furthermore, comprehensive venous thromboembolism prevention strategies, such as lower-extremity strength exercises, intermittent pneumatic compression of the calf, and LMWH injections, were applied during the early postoperative period. These factors may explain why LDEPI administration did not increase the incidence of early postoperative thromboembolic complications.
On the basis of the analysis of serum inflammatory cytokine levels, intravenous LDEPI reduced the secretion of proinflammatory cytokines (TNF-a and IL-1b) and increased the secretion of anti-inflammatory cytokines (IL-10). This is consistent with previous studies, in which intravenous EPI inhibited the secretion of proinflammatory cytokines, such as TNF-a, IL-1b, and IL-8, and enhanced the secretion of IL-10 via b2 receptors [23] , which elevate intracellular cAMP concentrations [11, 24, 25] . However, this effect is transient, and mainly occurs within 6 h postoperatively. In addition, the secretion of cytokines in groups TP and CT mainly peaked 3 h postoperatively, whereas the peak values appeared before 3 h postoperatively in group IV. This might be attributable to the different anti-inflammatory mechanisms of EPI and TXA. The anti-inflammatory effect of TXA occurs via antifibrinolytic mechanisms, which reduce the stimulation of fibrinolytic products on immune cells, whereas EPI has direct effects on immune cells, with stronger efficiency. As previously reported, EPI can alter neutrophil trafficking and upregulate IL-6 by b2 adrenergic receptors that impair wound healing [26] . In this study, there were no significant differences in the systemic levels of IL-6. We did not measure the topical levels of IL-6 near the incision; however, none of the patients reported any wound problems. Therefore, intravenous administration of LDEPI might have had a net antiinflammatory effect in THA patients, thereby reducing the early postoperative inflammatory responses.
This study has several limitations. First, to maximally reduce the systemic effect of EPI, the dose of EPI was low, and we had strict inclusion and exclusion criteria. Unstable hemodynamics, cerebrovascular conditions, glaucoma, hypokalemia, pheochromocytoma, thyrotoxicosis or depression may be contraindications to the use of EPI. Second, the age of patients was restricted to < 65 years. Third, the 1-month follow-up was relatively short, and this might have concealed the long-term incidence of complications, especially for thromboembolic complications, because it has been previously reported that the incidence of thromboembolic events decreased to a stable rate~10 weeks after hip arthroplasty [27] . These limitations may influence the generalizability of conclusions in this study.
In conclusion, LDPEI plus TXA could significantly reduce early postoperative total blood loss and alleviate inflammatory responses without increasing the early postoperative incidence of complications as compared with TXA alone in patients undergoing THA.
